Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2022 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial.
Coarelli G, Heinzmann A, Ewenczyk C, Fischer C, Chupin M, Monin ML, Hurmic H, Calvas F, Calvas P, Goizet C, Thobois S, Anheim M, Nguyen K, Devos D, Verny C, Ricigliano VAG, Mangin JF, Brice A, Tezenas du Montcel S, Durr A. Coarelli G, et al. Lancet Neurol. 2022 Mar;21(3):225-233. doi: 10.1016/S1474-4422(21)00457-9. Epub 2022 Jan 18. Lancet Neurol. 2022. PMID: 35063116 Clinical Trial.
Our aim was to test riluzole in a single genetic disease, spinocerebellar ataxia type 2. METHODS: We did a randomised, double-blind, placebo-controlled, multicentre trial (the ATRIL study) at eight national reference centres for rare diseases in France …
Our aim was to test riluzole in a single genetic disease, spinocerebellar ataxia type 2. METHODS: We did a randomise …
Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial.
Romano S, Coarelli G, Marcotulli C, Leonardi L, Piccolo F, Spadaro M, Frontali M, Ferraldeschi M, Vulpiani MC, Ponzelli F, Salvetti M, Orzi F, Petrucci A, Vanacore N, Casali C, Ristori G. Romano S, et al. Lancet Neurol. 2015 Oct;14(10):985-91. doi: 10.1016/S1474-4422(15)00201-X. Epub 2015 Aug 25. Lancet Neurol. 2015. PMID: 26321318 Clinical Trial.
BACKGROUND: Our previous study in patients with cerebellar ataxias of different causes showed significant benefit of riluzole after 8 weeks. We aimed to confirm these results in patients with spinocerebellar ataxia or Friedreich's ataxia in a 1- …
BACKGROUND: Our previous study in patients with cerebellar ataxias of different causes showed significant benefit of riluzole …
Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes.
Vogel AP, Folker J, Poole ML. Vogel AP, et al. Cochrane Database Syst Rev. 2014 Oct 28;2014(10):CD008953. doi: 10.1002/14651858.CD008953.pub2. Cochrane Database Syst Rev. 2014. PMID: 25348587 Free PMC article.
The 14th trial, involving a mixed group of participants with spinocerebellar ataxia, compared the effectiveness of nonspecific physiotherapy and occupational therapy within an inpatient hospital setting to no treatment. ...Riluzole was found to have a statist …
The 14th trial, involving a mixed group of participants with spinocerebellar ataxia, compared the effectiveness of nonspecific …
How to improve statistical power in a trial with SCA2 patients using natural history data.
Tran M, Poulet PE, Petit E, Durr A, Klockgether T, Ashizawa T, Coarelli G, du Montcel ST. Tran M, et al. Trials. 2026 Mar 5;27(1):297. doi: 10.1186/s13063-026-09591-w. Trials. 2026. PMID: 41787540 Free PMC article.
Randomized, double-blind, placebo-controlled trials are the gold standard for evaluating treatment effects, as they minimize biases. ...We aim to test these methods to the ATRIL study, which evaluated the efficacy of riluzole in patients with dominant cerebellar …
Randomized, double-blind, placebo-controlled trials are the gold standard for evaluating treatment effects, as they minimize biases. …